Cardisio's test system is currently being evaluated in ten further studies at various European medical centers. One of these studies, conducted at the SANA Heart Center in Cottbus, Germany, included 106 patients. The results, showing sensitivity of 95.3% and specificity of 90.3%, will be presented at the International Congress of the European Society of Cardiovascular and Endovascular Surgery in Padua, Italy, in May 2020.
Cardisio is CE-Marked and has begun selling the test system to general practitioners, cardiologists and hospitals in several European countries via resellers and distributors. Cardisio is currently evaluating partners and studies to support regulatory clearance and deployment in the United States and other countries.
"Cardisio embodies a new generation of medical diagnostic systems that are mobile and Internet-based, leveraging new Artificial Intelligence capabilities," said Meik Baumeister, co-founder and CEO of Cardisio. "The combination of classic cardiology coupled with intelligent high-performance algorithms offers us unprecedented opportunities to change how CAD is managed globally."
About Cardisio
Headquartered in Frankfurt, Germany, with offices in Berlin and San Francisco, Cardisio is a privately-held mobile health tech company that develops non-invasive, highly accurate tests for detecting coronary artery disease. Called Cardisiography, the test is CE-Marked and commercially available in several European countries.
SOURCE Cardisio
Back to HCB News
